Live Investor Briefing – Prescient Therapeutics

Prescient Therapeutics (ASX: PTX)

Live Investor Briefing

Register for an Upcoming Webcast

Please join us for a special investor briefing with Prescient Therapeutics CEO and MD Steven Yatomi-Clarke.

In the session, Steven will discuss:

  • An introduction into the amazing field of CAR-T, and how Prescient’s next gen CAR-T platform, OmniCAR, is seeking to take this burgeoning cancer field to the next level.
  • Our encouraging progress through clinical trials of Prescient’s foundational assets PTX-100 and PTX-200.

This is a live and interactive online session, and participants are encouraged to ask questions. Joining only requires an internet connection. Spots are limited, so secure yours today.

Book Your Spot

What is a 708 investor?

By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Markets have been engaged to help manage our investor communications.


Steven Yatomi-Clarke (Speak feature)

Steven Yatomi Clarke

CEO and Managing Director

Steven took over as CEO of Prescient Therapeutics in 2016 and has overseen its progression from start-up phase. Steven manages a team in Australia and the US and has been instrumental in strategy development; licensing; initiating and managing clinical trials; fundraising and business development. He has been a collaborator on various immunotherapy research projects.